Exelixis | EXEL - L'Utile Ante Imposte

Prezzo Delle Azioni
44.27
Cambio Giornaliero
-1.14 -2.51%
Mensile
6.04%
Annuale
25.38%
Q2 Previsione
43.06




L'Utile Ante Imposte Cambiamento Data
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
Agios Pharmaceuticals USD -109.06M 5.62M 2025-12
Akebia Therapeutics USD -11.24M 12.39M 2025-12
Amgen USD 3.92B 2.35B 2025-09
AstraZeneca USD 3.24B 117M 2025-09
Bayer EUR -1.16B 735M 2025-09
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Cytokinetics USD -183.03M 123.15M 2025-12
Eisai JPY 22B 7.47B 2025-12
Eli Lilly USD 7.23B 456M 2025-09
Esperion Therapeutics USD 63.67M 95M 2025-12
Exelixis USD 252.69M 275K 2025-12
Genmab DKK 55M 427M 2025-12
Glaxosmithkline GBP 2.46B 569M 2025-09
Incyte USD 389.94M 92.37M 2025-12
Ionis Pharmaceuticals USD -228M 99M 2025-12
MacroGenics USD -14.93M 31.75M 2025-12
Merck USD 6.74B 22M 2025-09
Moderna USD -187M 631M 2025-09
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Novartis USD 4.64B 445M 2025-12
Pfizer USD 3.33B 290M 2025-09
Puma Biotechnology USD 20.61M 24.76M 2024-09
Sanofi EUR -1.16B 6.23B 2025-12
Takeda JPY 133.86B 105.69B 2025-12
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
Xencor USD -4.27M 1.76M 2025-12